These 3 Stocks Might (Still) Be a Little Too Expensive

·5 min read

Shares of drugmaker Eli Lilly (NYSE: LLY) have suffered the same occasional tumble that its pharma peers and the broad market have taken this year. Whereas the Dow Jones Industrial Average is down 13% year to date and the Dow Jones Pharmaceutical Index is just slightly better than breakeven, Lilly shares are up more than 18% since the end of 2021. Much credit goes to Eli Lilly's COVID-19 treatment combination of bamlanivimab and etesevimab although its diabetes treatment Trulicity has been a heavy hitter as well.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting